6 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 14 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 6, Recruiting 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 7 | Recruiting 3, Terminated 2, Active not recruiting 1, Completed 1 |
Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome) Chang Ji'an capsule, Chang Ji'an capsule mimic - IBS, Diarrhea Predominant | Phase 3 | Not yet recruiting | Beijing Hospital of Traditional Chinese Medicine | 636 | 2026-05-31 | 2026-05-28 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Saccharomyces Boulardii 250 MG, Placebo 250 mg - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 3 | Recruiting | Biocodex | 406 | 2025-10-22 | 2025-11-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis TMB-001, Matching Vehicle - Ichthyosis | Phase 3 | Completed | LEO Pharma | 153 | 2022-06-21 | 2026-05-22 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream - Sjogren-Larsson Syndrome | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 11 | 2018-07-18 | 2023-02-09 |
| Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side - Lamellar Ichthyosis | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 6 | 2010-10-01 | 2026-06-17 |
| Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) Rezular 15mg, Placebo, Rezular - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Completed | AGI Therapeutics, Inc. | 711 | 2007-09-01 | 2009-06-11 |
| Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis Liarozole - Ichthyosis, Lamellar | Phase 2 / Phase 3 | Completed | Stiefel, a GSK Company | 98 | 2006-01-01 | 2011-09-26 |
| Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis monolaurin cream - Ichthyosis | Phase 3 | Completed | Cellegy Pharmaceuticals | 90 | 1996-09-01 | 2015-03-25 |
Netherton Syndrome (6) · Ichthyosis Bullosa of Siemens (3) · Ichthyosis, Lamellar (2) · Irritable Bowel Syndrome (1) · Rare Diseases (1) · Sjogren-Larsson Syndrome (1) · Skin Diseases (1)
Congenital Abnormalities (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Infant, Newborn, Diseases (14) · Keratosis (14) · Skin Abnormalities (14) · Skin and Connective Tissue Diseases (14) · Skin Diseases (13) · Genetic Diseases, Inborn (12) · Skin Diseases, Genetic (12) · Ichthyosiform Erythroderma, Congenital (8) · Abnormalities, Multiple (6) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Digestive System Diseases (1)
Injections (1) · Skin Cream (1) · liarozole (1) · reproxalap (1) · spesolimab (1) · tebufenozide (1)
Quoin Pharmaceuticals (4) · AGI Therapeutics, Inc. (1) · Aldeyra Therapeutics, Inc. (1) · Beijing Hospital of Traditional Chinese Medicine (1) · Biocodex (1) · Boehringer Ingelheim (1) · Cellegy Pharmaceuticals (1) · Centre Hospitalier Universitaire de Nice (1) · LEO Pharma (1) · Stiefel, a GSK Company (1) · University Hospital, Toulouse (1)
United States (8) · France (5) · Germany (3) · Italy (3) · Canada (2) · China (2) · Netherlands (2) · Portugal (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Dominican Republic (1) · Israel (1) · Japan (1)
Tony Andrasfay (2) · Carl R. Thornfeldt (1) · Chiaverini Christine, Dr (1) · Koen van Rossem, MD, PhD (1) · Oana Bernard, DR (1)